Open Label Study of Isavuconazole in the Treatment of Patients With Aspergillosis and Renal Impairment or of Patients With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi

Inclusion Criteria:

- Patients meeting EORTC/MSG (European Organization for the Research and Treatment of
Cancer/Mycoses Study Group) definition of proven or culture positive probable IFD
(invasive fungal disease) caused by rare molds, yeasts, or dimorphic fungi (i.e.
fungal pathogens other than Aspergillus or Candida species) whether renally impaired
or not (including dialysis) who require primary therapy for their IFD at the time of
enrollment.

OR

- Patients who have proven or probable zygomycosis, whether renally impaired or not
(including dialysis), who require primary therapy. Zygomycosis must be documented by
culture or histology / cytology.

Exclusion Criteria:

- a known condition of the patient that may jeopardize adherence to the protocol
requirements

- Patients who are unlikely to survive 30 days

- Patients with a body weight < 40 kg

- Women who are pregnant or breastfeeding